Symbios Technologies Announces Five-Year Master Research and Development Agreement with Colorado State University

Share Article

Symbios is implementing a collaborative research partnership for its dynamic plasma activation technology through the Office of the Vice President for Research at Colorado State University.

Symbios logo
CSU has been an outstanding resource to help Symbios commercialize our groundbreaking plasma technology. This agreement will help facilitate further collaborative work with the CSU Flint Animal Cancer Center as well as other research faculty...

Symbios Technologies, Inc., a world-leading developer of dynamic aqueous plasma technology platforms, announced today that the company has engaged in a collaborative research partnership with Colorado State University (CSU) through a five-year Master Research and Development Agreement (MRDA) with the CSU Office of the Vice President for Research. This agreement is designed to further the commercialization of the company’s technology and the mission of CSU as a modern land-grant university.

The MRDA outlines the working relationship between Symbios and CSU’s world-renowned programs in agriculture, engineering, veterinary medicine, biomedical sciences, chemistry, oncology, biology, and many other disciplines that have established CSU as an international academic and research leader. Through the MRDA, Symbios has sponsored research agreements, technology transfer, and joint intellectual property development via faculty collaborations and employment.

Currently, Symbios is collaborating with CSU's Dr. Douglas Thamm, professor of Oncology and director of Clinical Research at the CSU Flint Animal Cancer Center. Dr. Thamm, a veterinary oncologist, is a consultant on Symbios' current National Institutes of Health (NIH) grant from the National Cancer Institute.

In addition, Symbios engaged CSU graduate Jessica Joslin, who has a doctorate in physical chemistry, as a National Science Foundation (NSF) postdoctoral fellow. Joslin was subsequently hired as the company’s senior scientist and serves as the principal investigator on two NIH grants in collaboration with CSU.

Through the partnership, Symbios has provided multiple internships to CSU engineering students; James McCall was recently hired as the company’s chemical & biological engineer. CSU also hosts Symbios as one of the companies in residence at the CSU Research Innovation Center at the Infectious Disease Research Center on the Foothills Campus, further facilitating contracts with multiple laboratories and manufacturing facilities on campus.

“The Office of the Vice President for Research helps fulfill the land-grant mission of CSU by fostering and supporting the research enterprise, promoting scholarship and artistry, instilling a culture of integrity, and capitalizing on opportunities to address global challenges,” said Mark Wdowik, assistant vice president for Research & Industry Partnerships. “The collaboration with Symbios has resulted in a significant investment in CSU research. We anticipate many times that level of engagement, as well as possible licensing of CSU and jointly-developed technologies, as part of Symbios' ongoing collaborations with CSU faculty and students, centers and startup companies, and other private and public partners.”

Justin Bzdek, Symbios president & CEO, said, “CSU has been an outstanding resource to help Symbios commercialize our groundbreaking plasma technology. This agreement will help facilitate further collaborative work with the CSU Flint Animal Cancer Center as well as other research faculty who can utilize our low-power, continuous flow plasma technology to develop applications to treat some of the most difficult to remediate industrial processes and wastewater and generate advanced chemotherapeutics and anti-infective products to reduce the global impact of deadly diseases.”

Alan Rudolph, vice president for Research at CSU, also hailed this partnership. “Collaborative research relationships like the one with Symbios play a critical role in driving innovations from laboratories to the marketplace," he said. "As companies seek new product pipelines, more of them are turning to CSU, which is well-known for its core technical and research and development strengths, its ability to solve today’s complex problems across a broad range of industries, and its capabilities to provide independent, third-party assessments.”

About Symbios Technologies

Symbios Technologies, Inc. is a world-leading developer of dynamic aqueous plasma technology platforms for water treatment, specialty manufacturing, and biotherapeutic applications. The company, working with its university, government, and industrial partners, is commercializing its disruptive advanced low-cost aqueous plasma oxidation technology, the Symbios Tubular Plasma Reactor™ (TPR4000™), to clean water, preserve the environment, and protect human health while improving production economics and sustainability. Symbios Technologies’ modular reactor is low in capital cost, able to replace existing energy-hungry or poor-performing advanced oxidation processes, while reducing or eliminating the use of biocides and/or chemical additives, thus improving the overall maintenance cost of water treatment systems. The TPR4000 also has the potential to generate less toxic chemotherapy drugs and safer anti-infectives to reduce the global impact of deadly diseases. For more information, go to http://www.symbiosplasma.com/.

About Colorado State University

Founded in 1870 as the Colorado Agricultural College, Colorado State University is now among the nation's leading research universities. Located in Fort Collins, CSU currently enrolls more than 33,000 students, and has more than 1,800 faculty members working in eight colleges.

Colorado State University is recognized as a premier research institution and routinely ranks as one of the top American universities without a medical school in research expenditures. In Fiscal Year 2016, CSU research expenditures totaled $332 million; this was the ninth consecutive year research expenditures at the university have topped $300 million.

More information is available at http://www.colostate.edu.

About CSU Infectious Disease Research Center, Research Innovation Center, and Bioscience Business Incubator

The IDRC provides a secure, state-of-the-art facility for university investigators, government scientists, and industry representatives to collaboratively research the basic biology, biochemistry, molecular biology, and epidemiology of bacteria and viruses that cause human and animal diseases. The Center provides a research environment for developing new scientific discoveries, vaccines, methods of diagnosis, and therapeutic agents for infectious agents. The CSU Research Innovation Center is a 72,000 sq. ft. research center that fosters private and public sector collaboration. The CSU Bioscience Business Incubator, located within the Research Innovation Center, is aligned with the mission of the University to provide a return on public investment in research by generating economic opportunities through new companies focused on problems or issues of public interest.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Justin Bzdek
@SymbiosPlasma
Follow >
Visit website